Delving into the Latest Updates on SC-10914 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PARP1 x PARP2

Action

inhibitors

Mechanism

PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]

Active Indication

Ovarian Serous TumorBRCA mutation positive Breast CancerMetastatic castration-resistant prostate cancer+ [1]

Inactive Indication

Locally advanced breast cancerMetastatic breast cancerNeoplasm Metastasis

Originator Organization

Qingfeng Pharmaceutical Group Co.Ltd

Active Organization

Piistech

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

Primary objective: To evaluate the efficacy of SC10914 as a monotherapy in patients with advanced ovarian cancer and germline BRCA mutations who have failed 2 or more lines of chemotherapy. Secondary objective: To evaluate the safety and pharmacokinetic characteristics of SC10914 as a monotherapy in patients with advanced ovarian cancer and germline BRCA mutations who have failed 2 or more lines of chemotherapy.

Start Date24 Nov 2020

Sponsor / Collaborator

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

[+1]

CTR20201968

/ CompletedPhase 1

食物对SC10914 药代动力学影响的Ⅰ期临床研究

[Translation] Phase I clinical study on the effect of food on the pharmacokinetics of SC10914

主要目的： - 评价健康受试者口服给药SC10914片后，食物对SC10914及其代谢物的PK影响次要目的： - 观察健康受试者服用SC10914片后的安全性 - 初步探索健康受试者服用SC10914片后的物质平衡及代谢转化途径

[Translation]

Primary purpose: - To evaluate the effect of food on the PK of SC10914 and its metabolites after oral administration of SC10914 tablets to healthy subjects Secondary purpose: - To observe the safety of SC10914 tablets after healthy subjects took them - To preliminarily explore the material balance and metabolic transformation pathways after healthy subjects took SC10914 tablets

Start Date03 Nov 2020

Sponsor / Collaborator

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with SC-10914

Login to view more data

100 Translational Medicine associated with SC-10914

Login to view more data

100 Patents (Medical) associated with SC-10914

Login to view more data

100 Deals associated with SC-10914

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Serous Tumor	Phase 2	China	Piistech	24 Nov 2020
Ovarian Serous Tumor	Phase 2	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	24 Nov 2020
BRCA mutation positive Breast Cancer	Phase 2	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	01 Jul 2020
BRCA mutation positive Breast Cancer	Phase 2	China	Piistech	01 Jul 2020
Metastatic castration-resistant prostate cancer	Phase 2	China	Piistech	15 Jun 2020
Metastatic castration-resistant prostate cancer	Phase 2	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	15 Jun 2020
Locally advanced breast cancer	Phase 1	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	12 Aug 2020
Metastatic breast cancer	Phase 1	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	12 Aug 2020
Neoplasm Metastasis	Phase 1	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	12 Aug 2020
Advanced Malignant Solid Neoplasm	Phase 1	China	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	01 Oct 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02940132 (ASCO 12020 \| ASCO 22020) Manual	Phase 1	HR-positive/HER2-low Solid Tumors BRCA Mutation (germline)	52	SC-10914	(nehegpzfzg) = rorvfsgpgt unzpkjxhmx (cvysbrdkkk ) View more	Positive	29 May 2020